This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Alex Nisthal, PhD
Group Leader, Protein Engineering at Xencor


Dr. Nisthal is a Group Leader in the Protein Engineering department at Xencor. Since joining Xencor in 2016, Dr. Nisthal has led the early development of several drug programs for oncology, including 2+1 CD3 bispecifics and engineered cytokines. He has made contributions to diverse efforts within Xencor, including in silico target discovery, antibody discovery library design, and modern data management. Prior to Xencor Dr. Nisthal worked as a staff scientist at Caltech, where he contributed to the protein engineering of broadly neutralizing antibodies against influenza as well as enzymes for industrial biotech applications. He holds a Ph.D. in Biochemistry and Molecular Biophysics from Caltech, and a B.S. in Biotechnology from CSU Pomona.

Agenda Sessions

  • Engineered Cytokines for Cancer Immunotherapy